本研究旨在探讨精确肝切除术治疗原发性肝癌的安全性和疗效。从2020年2月至2021年2月，对我院收治的98例原发性肝癌患者进行随机对照试验，根据不同的手术方法，分为对照组（常规肝切除术）和研究组（精确肝切除术）各49例。统计两组手术情况、并发症和随访结果，并观察术前和术后1周两组的肝功能和免疫功能。研究组的手术时间、术中出血量、住院时间和肛门排气时间均显著低于对照组(P < 0.05)。术后1周，研究组的AST、TBiL、ALT和ALB水平下降，显著高于对照组(P < 0.05)；研究组的CD4+、CD3+和CD4+/CD8+水平显著高于对照组(P < 0.05)。研究组的并发症发生率显著低于对照组(P < 0.05)。随访2年后，研究组的复发率和死亡率均低于对照组(P < 0.05)；两组间转移率的差异在统计学上无显著性(P > 0.05)。精确肝切除术可有效治疗原发性肝癌，具有较高的安全性，在临床实践中有推广价值。 © 2023. BioMed Central Ltd., part of Springer Nature.

The aim of this study was to investigate the safety and efficacy of precision hepatectomy in the treatment of primary liver cancer.An randomized controlled trial of 98 patients with primary liver cancer admitted to our hospital from February 2020 to February 2021 were analyzed for the study, and they were divided into 49 cases each in the control group (conventional hepatectomy) and the study group (precision hepatectomy) according to the different surgical methods. The surgical condition, complications and follow-up results of the two groups were counted, and the liver function and immune function of the two groups were observed before and 1 week after surgery.The operation time, intraoperative bleeding, hospitalization time and anal venting time in the study group were less than those in the control group (P < 0.05). One week after surgery, AST, TBiL, ALT and ALB levels decreased, with in the study group significantly higher than those in the control group (P < 0.05); CD4+, CD3 + and CD4+/CD8 + levels were significantly higher in the study group (P < 0.05). The incidence of complications in the study group was significantly lower than that in the control group (P < 0.05). After 2 years of follow-up, the recurrence rate and mortality rate of the study group were lower than those of the control group (P < 0.05); the difference was not statistically significant when comparing the metastasis rate between the two groups (P > 0.05).Precision hepatectomy can effectively treat primary liver cancer with high safety and could be promoted in clinical practice.© 2023. BioMed Central Ltd., part of Springer Nature.